转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

亚硝基化谷胱甘肽还原酶（GSNOR）: 一个调控炎症反应的新分子

2014-01-03 吴凯源 张玉英 粟文婷 陈畅 生物化学与生物物理学进展

亚硝基化谷胱甘肽还原酶GSNORNO炎症因子
关注

    炎症因子的表达调控是炎症反应的关键步骤，与自身免疫疾病以及癌症等密切相关．一氧化氮(nitric oxide，NO)在炎症因子表达调控中具有重要作用，但已有的研究多关注于NO合成对炎症因子的调控作用，而对NO代谢的作用知之甚少．亚硝基化谷胱甘 肽还原酶(S-nitrosoglutathione reductase，GSNOR)是体内NO信号通路代

    炎症因子的表达调控是炎症反应的关键步骤，与自身免疫疾病以及癌症等密切相关．一氧化氮(nitric oxide，NO)在炎症因子表达调控中具有重要作用，但已有的研究多关注于NO合成对炎症因子的调控作用，而对NO代谢的作用知之甚少．亚硝基化谷胱甘 肽还原酶(S-nitrosoglutathione reductase，GSNOR)是体内NO信号通路代谢调控的关键蛋白．本研究发现脂多糖(lipopolysaccharide，LPS)在 RAW264.7细胞中上调诱导型一氧化氮合酶(inducible nitric oxide synthase，iNOS)的同时下调GSNOR的转录和蛋白质表达，该下调作用依赖MEK1/2、p38和PI3K信号通路．抑制GSNOR可促进 LPS诱导的炎症因子IL-1β、IL-6和TNF-α表达，而过表达GSNOR作用相反．抗炎症药物曲古抑菌素A (trichostatin A，TSA)能够挽回LPS对GSNOR的下调作用，并且GSNOR抑制剂削弱了TSA对炎症因子IL-6和TNF-α转录的抑制效应．这些结果表 明：GSNOR

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1923233, encodeId=6722192323387, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jun 19 04:50:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068135, encodeId=37c8206813559, content=<a href='/topic/show?id=437a1649005' target=_blank style='color:#2F92EE;'>#SNO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16490, encryptionId=437a1649005, topicName=SNO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 18 17:50:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320806, encodeId=70bb1320806c4, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-06-19 12498761m56暂无昵称

    #新分子#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1923233, encodeId=6722192323387, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jun 19 04:50:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068135, encodeId=37c8206813559, content=<a href='/topic/show?id=437a1649005' target=_blank style='color:#2F92EE;'>#SNO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16490, encryptionId=437a1649005, topicName=SNO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 18 17:50:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320806, encodeId=70bb1320806c4, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-18 zhaojie88

    #SNO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1923233, encodeId=6722192323387, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jun 19 04:50:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068135, encodeId=37c8206813559, content=<a href='/topic/show?id=437a1649005' target=_blank style='color:#2F92EE;'>#SNO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16490, encryptionId=437a1649005, topicName=SNO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 18 17:50:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320806, encodeId=70bb1320806c4, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 lsj628

    #炎症反应#

    0